REG - Nuformix PLC - Posting of Annual Report and Notice of AGM

NuformixAnnouncement

01/08/2022 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA4720Ua&default-theme=true

RNS Number : 4720U  Nuformix PLC  01 August 2022

1 August 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

Posting of Annual Report and Notice of AGM

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual Financial Report for the year ended 31 March 2022 (the "Annual
Financial Report 2022") and the 2022 Notice of Annual General Meeting ("AGM")
are today being posted to its shareholders:

 

A full pdf version of the Annual Financial Report 2022 together with the
Notice of Annual General Meeting is available for download from the Investor
Information section on the Company's website www.nuformix.com
(http://www.nuformix.com) .

 

The Annual Financial Report 2022 will be filed with the Registrar of Companies
in due course and copies can be obtained from the Company Secretary, SGH
Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.

 

The Annual General Meeting will be held on 25 August 2022 at 2.00 pm at the
offices of Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London,
EC3V 0HR.

 

Enquiries:

 

 Nuformix plc
 Dr Julian Gilbert, Non-executive Chairman         Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFLFLLTLILIIF